RELB anticorps

N° du produit ABIN4913565

Cet anticorps anti-RELB est un anticorps Souris Monoclonal détectant RELB dans WB. Adapté pour Humain et Souris.

Aperçu rapide pour RELB anticorps (ABIN4913565)

Antigène: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Reactivité: Humain, Souris

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp RELB est non-conjugé

Application: Western Blotting (WB)

Clone: 4C5

Détail du produit anti-RELB anticorps

Réactivité croisée: Humain, Souris

Purification: Purified by Protein G.

Immunogène: This RELB antibody is generated from a mouse immunized with a recombinant protein human RELB.

Isotype: IgG1

Information d'application

Indications d'application: WB 1:300-5000

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.5 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C for 12 months.

Date de péremption: 12 months

Détails sur RELB

Antigène: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Autre désignation: RELB

Sujet:

Synonyms: IREL, I-REL, REL-B, Transcription factor RelB, RELB

Background: NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52.

ID gène: 5971

UniProt: Q01201

Pathways: Signalisation NF-kappaB, Signalisation RTK